A recent study published in PubMed highlights health literacy levels among individuals with systemic sclerosis, utilizing data from the Scleroderma Patient-Centered Intervention Network (SPIN). This cross-sectional study aims to inform future interventions to improve patient outcomes.

CAR-T cell therapy, traditionally used for blood cancers, is being explored for autoimmune diseases such as lupus, multiple sclerosis, and scleroderma. Experts believe this innovative approach could revolutionize treatment for these challenging conditions.

Yale School of Medicine is advancing CAR-T therapy beyond oncology, initiating clinical trials for autoimmune diseases such as lupus, multiple sclerosis, and scleroderma. This innovative approach could reshape treatment paradigms for these conditions.

A recent study highlights the complexities of managing scleroderma renal crisis and associated cardiac complications in a young patient with mixed connective tissue disease (MCTD). The case emphasizes the need for further research into the implications of anti-U3 RNP and anti-RNA polymerase III antibodies.

Recent research highlights the occurrence of scleroderma renal crisis in patients with mixed connective tissue disease, providing new insights into this rare complication. Understanding this association may improve clinical management and patient outcomes.